The authors for the abstract on Medical management of brain metastases, will correct their publication.
All 3 authors would be well aware of the drugs selected in ALLIANCE study, they will be very embarrassed with their lack of proof reading..
The study arms from the ALLIANCE study is as follows:-
"Experimental: Arm I (CDK gene mutation)Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.Intervention: Drug: Abemaciclib
Experimental: Arm II (PI3K gene mutation)Patients receive PI3K inhibitor GDC-0084 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.Intervention: Drug: PI3K Inhibitor GDC-0084
Experimental: Arm III (NTRK/ROS1 gene mutation)Patients receive entrectinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.Intervention: Drug: Entrectinib"
Regards.
- Forums
- ASX - By Stock
- KZA
- Across the pond...Nasdaq: KZIA
Across the pond...Nasdaq: KZIA, page-237
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online